Shares of Athenex Inc (NASDAQ:ATNX) have been given an average recommendation of “Buy” by the six ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $27.64.
Several equities analysts have recently weighed in on ATNX shares. JPMorgan Chase & Co. started coverage on Athenex in a research note on Wednesday, October 18th. They issued a “neutral” rating and a $22.20 price objective on the stock. Credit Suisse Group started coverage on Athenex in a research note on Monday, September 18th. They issued an “outperform” rating and a $25.00 price objective on the stock. Royal Bank of Canada started coverage on Athenex in a research note on Thursday, September 14th. They issued an “outperform” rating and a $35.00 price objective on the stock. Laidlaw started coverage on Athenex in a research note on Tuesday, September 19th. They issued a “buy” rating and a $36.00 price objective on the stock. Finally, BidaskClub lowered Athenex from a “hold” rating to a “sell” rating in a research note on Thursday.
Athenex (ATNX) opened at $15.94 on Thursday. Athenex has a 52 week low of $11.21 and a 52 week high of $20.79.
Athenex Company Profile
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.